These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 8221668)

  • 1. Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangement: clinical implications.
    Jelinek DF; Ahmann GJ; Greipp PR; Jalal SM; Westendorf JJ; Katzmann JA; Kyle RA; Lust JA
    Cancer Res; 1993 Nov; 53(21):5320-7. PubMed ID: 8221668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic basis for dosage sensitivity in Arabidopsis thaliana.
    Henry IM; Dilkes BP; Comai L
    PLoS Genet; 2007 Apr; 3(4):e70. PubMed ID: 17465685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High clonal diversity and spatial genetic admixture in early prostate cancer and surrounding normal tissue.
    Zhang N; Harbers L; Simonetti M; Diekmann C; Verron Q; Berrino E; Bellomo SE; Longo GMC; Ratz M; Schultz N; Tarish F; Su P; Han B; Wang W; Onorato S; Grassini D; Ballarino R; Giordano S; Yang Q; Sapino A; Frisén J; Alkass K; Druid H; Roukos V; Helleday T; Marchiò C; Bienko M; Crosetto N
    Nat Commun; 2024 Apr; 15(1):3475. PubMed ID: 38658552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis.
    Poos AM; Prokoph N; Przybilla MJ; Mallm JP; Steiger S; Seufert I; John L; Tirier SM; Bauer K; Baumann A; Rohleder J; Munawar U; Rasche L; Kortüm KM; Giesen N; Reichert P; Huhn S; Müller-Tidow C; Goldschmidt H; Stegle O; Raab MS; Rippe K; Weinhold N
    Blood; 2023 Nov; 142(19):1633-1646. PubMed ID: 37390336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-Frequency Dielectrophoresis Reveals That Distinct Bio-Electric Signatures of Colorectal Cancer Cells Depend on Ploidy and Nuclear Volume.
    Duncan JL; Bloomfield M; Swami N; Cimini D; Davalos RV
    Micromachines (Basel); 2023 Sep; 14(9):. PubMed ID: 37763886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mathematical Modeling of Clonal Interference by Density-Dependent Selection in Heterogeneous Cancer Cell Lines.
    Veith T; Schultz A; Alahmari S; Beck R; Johnson J; Andor N
    Cells; 2023 Jul; 12(14):. PubMed ID: 37508513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting phosphoglycerate dehydrogenase in multiple myeloma.
    Elsaadi S; Steiro I; Abdollahi P; Vandsemb EN; Yang R; Slørdahl TS; Rø TB; Menu E; Sponaas AM; Børset M
    Exp Hematol Oncol; 2021 Jan; 10(1):3. PubMed ID: 33397437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Interleukin-6 Inducible Gene PDZ-Binding Kinase Promotes Tumor Growth of Multiple Myeloma Cells.
    Ota A; Hanamura I; Karnan S; Inaguma S; Takei N; Lam VQ; Mizuno S; Kanasugi J; Wahiduzzaman M; Rahman ML; Hyodo T; Konishi H; Tsuzuki S; Ikeda H; Takami A; Hosokawa Y
    J Interferon Cytokine Res; 2020 Aug; 40(8):389-405. PubMed ID: 32721246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemical, Physical and Biological Triggers of Evolutionary Conserved Bcl-xL-Mediated Apoptosis.
    Ianevski A; Kulesskiy E; Krpina K; Lou G; Aman Y; Bugai A; Aasumets K; Akimov Y; Bulanova D; Gildemann K; Arutyunyan AF; Susova OY; Zhuze AL; Ji P; Wang W; Holien T; Bugge M; Zusinaite E; Oksenych V; Lysvand H; Gerhold JM; Bjørås M; Johansen P; Waage A; Heckman CA; Fang EF; Kainov DE
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32630560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biallelic loss of FAM46C triggers tumor growth with concomitant activation of Akt signaling in multiple myeloma cells.
    Kanasugi J; Hanamura I; Ota A; Karnan S; Lam VQ; Mizuno S; Wahiduzzaman M; Rahman ML; Hyodo T; Konishi H; Tsuzuki S; Hosokawa Y; Takami A
    Cancer Sci; 2020 May; 111(5):1663-1675. PubMed ID: 32176823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis.
    Sarin V; Yu K; Ferguson ID; Gugliemini O; Nix MA; Hann B; Sirota M; Wiita AP
    Leukemia; 2020 Oct; 34(10):2754-2765. PubMed ID: 32123307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma.
    Issa ME; Takhsha FS; Chirumamilla CS; Perez-Novo C; Vanden Berghe W; Cuendet M
    Clin Epigenetics; 2017; 9():17. PubMed ID: 28203307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells.
    Baranowska K; Misund K; Starheim KK; Holien T; Johansson I; Darvekar S; Buene G; Waage A; Bjørkøy G; Sundan A
    Oncotarget; 2016 Oct; 7(43):70845-70856. PubMed ID: 27683126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting executioner procaspase-3 with the procaspase-activating compound B-PAC-1 induces apoptosis in multiple myeloma cells.
    Zaman S; Wang R; Gandhi V
    Exp Hematol; 2015 Nov; 43(11):951-962.e3. PubMed ID: 26257207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis beyond the cancer clone(s) in multiple myeloma.
    Bianchi G; Munshi NC
    Blood; 2015 May; 125(20):3049-58. PubMed ID: 25838343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma.
    Bianchi G; Ghobrial IM
    Curr Cancer Ther Rev; 2014; 10(2):70-79. PubMed ID: 25705146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma.
    Mithraprabhu S; Kalff A; Chow A; Khong T; Spencer A
    Epigenetics; 2014 Nov; 9(11):1511-20. PubMed ID: 25482492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple myeloma dell-derived microvesicles are enriched in CD147 expression and enhance tumor cell proliferation.
    Arendt BK; Walters DK; Wu X; Tschumper RC; Jelinek DF
    Oncotarget; 2014 Jul; 5(14):5686-99. PubMed ID: 25015330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of the source of elevated hepatocyte growth factor levels in multiple myeloma patients.
    Rampa C; Tian E; Våtsveen TK; Buene G; Slørdahl TS; Børset M; Waage A; Sundan A
    Biomark Res; 2014 Apr; 2(1):8. PubMed ID: 24716444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeleton.
    Mithraprabhu S; Khong T; Spencer A
    Cell Death Dis; 2014 Mar; 5(3):e1134. PubMed ID: 24651437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.